期刊
JOURNAL OF HEPATOLOGY
卷 60, 期 4, 页码 855-865出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2013.11.031
关键词
mTOR; HCC; Rapamycin; Rapalogs; Second generation mTOR inhibitors
资金
- Intramural Research Program of the NIH
- National Cancer Institute
- Center for Cancer Research
- Schweizerische Stifung fur Medizinisch- Biologische Stipendien [PASMP-3_140071]
- Fondation Monahan
- Prix Amgen pour la Recherche et l'Innovation en oncologie digestive
Mechanistic target of rapamycin (mTOR) regulates cell growth, metabolism and aging in response to nutrients, cellular energy stage and growth factors. mTOR is frequently up-regulated in cancer including hepatocellular carcinoma (HCC) and is associated with bad prognosis, poorly differentiated tumors, and earlier recurrence. Blocking mTOR with rapamycin and first generation mTOR inhibitors, called rapalogs, has shown promising reduction of HCC tumor growth in preclinical models. Currently, rapamycin/rapalogs are used in several clinical trials for the treatment of advanced HCC, and as adjuvant therapy in HCC patients after liver transplantation and TACE. A second generation of mTOR pathway inhibitors has been developed recently and is being tested in various clinical trials of solid cancers, and has been used in preclinical HCC models. The results of series of clinical trials using mTOR inhibitors in HCC treatment will emerge in the near future. Published by Elsevier B. V. on behalf of the European Association for the Study of the Liver.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据